Renal Cancer
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.
November 19, 2024
Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram.
November 18, 2024
Primary tumor ablation in metastatic renal cell carcinoma.
November 15, 2024
Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.
November 15, 2024
Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma.
November 14, 2024
Urine leak and vascular complications following robotic partial nephrectomy: a contemporary single-center experience.
November 14, 2024
High RRM2 Correlates with Mitochondrial and Immune Responses in the Eosinophilic Subtype of Clear Cell Renal Cell Carcinoma.
November 12, 2024
Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma.
November 11, 2024
Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study.
November 11, 2024
First and Second-line Treatments in Metastatic Renal Cell Carcinoma.
November 8, 2024
Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer.
November 8, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
November 7, 2024
C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer.
November 7, 2024
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.
November 6, 2024